Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia.
Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia.
复制标题
复发或难治性急性髓性白血病靶向疗法的抗药性机制。
DOI：
10.1016/j.exphem.2022.04.001
复制
发表时间：
2022-07
影响因子：
2.6
通讯作者：
Li, Qing
中科院分区：
文献类型：
--
作者：
Kropp, Erin M.;Li, Qing
急性髓性白血病（AML）是一种侵袭性克隆造血疾病，尽管接受了强化治疗，但复发率和难治性疾病的发生率很高。传统上，复发或难治性急性髓细胞白血病的耐药性和长期生存率都很低。近年来，随着对白血病发生机理认识的不断深入，靶向疗法应运而生。这些疗法为强化化疗提供了新的选择，延长了复发或难治性急性髓细胞白血病患者的生存期。遗憾的是，相当一部分患者对这些疗法没有反应，大多数最初有反应的患者会复发。本综述将重点探讨复发或难治性急性髓细胞性白血病患者对靶向疗法的耐药机制。
急性髓细胞性白血病靶向疗法后复发和耐药的拟议机制。图由 biorender.com 绘制。
Acute myeloid leukemia (AML) is an aggressive disease of clonal hematopoiesis with a high rate of relapse and refractory disease despite intensive therapy. Traditionally, relapsed or refractory AML has increased therapeutic resistance and poor long-term survival. In recent years, advancements in the mechanistic understanding of leukemogenesis has allowed for the development of targeted therapies. These therapies offer novel alternatives to intensive chemotherapy and have prolonged survival in relapsed or refractory AML. Unfortunately, a significant portion of patients do not respond to these therapies and relapse occurs in most patients who initially responded. This review will focus on the mechanisms of resistance to targeted therapies in relapsed or refractory AML. Proposed mechanisms of relapse and resistance following targeted therapies in AML. Figure created with biorender.com.
登录
查看更多内容
影响因子：
11.2
作者：
Alotaibi AS;Yilmaz M;Kanagal-Shamanna R;Loghavi S;Kadia TM;DiNardo CD;Borthakur G;Konopleva M;Pierce SA;Wang SA;Tang G;Guerra V;Samra B;Pemmaraju N;Jabbour E;Short NJ;Issa GC;Ohanian M;Garcia-Manero G;Bhalla KN;Patel KP;Takahashi K;Andreeff M;Cortes JE;Kantarjian HM;Ravandi F;Daver N
通讯作者：
Daver N
影响因子：
64.5
作者：
Burgess MR;Hwang E;Mroue R;Bielski CM;Wandler AM;Huang BJ;Firestone AJ;Young A;Lacap JA;Crocker L;Asthana S;Davis EM;Xu J;Akagi K;Le Beau MM;Li Q;Haley B;Stokoe D;Sampath D;Taylor BS;Evangelista M;Shannon K
通讯作者：
Shannon K
DOI：
10.1016/s2352-3026(20)30210-6
发表时间：
2020-10
期刊：
The Lancet. Haematology
影响因子：
--
作者：
DiNardo CD;Maiti A;Rausch CR;Pemmaraju N;Naqvi K;Daver NG;Kadia TM;Borthakur G;Ohanian M;Alvarado Y;Issa GC;Montalban-Bravo G;Short NJ;Yilmaz M;Bose P;Jabbour EJ;Takahashi K;Burger JA;Garcia-Manero G;Jain N;Kornblau SM;Thompson PA;Estrov Z;Masarova L;Sasaki K;Verstovsek S;Ferrajoli A;Weirda WG;Wang SA;Konoplev S;Chen Z;Pierce SA;Ning J;Qiao W;Ravandi F;Andreeff M;Welch JS;Kantarjian HM;Konopleva MY
通讯作者：
Konopleva MY
影响因子：
20.3
作者：
Chen, Wen-Lian;Wang, Jing-Han;Jia, Wei
通讯作者：
Jia, Wei
影响因子：
158.5
作者：
DiNardo, C. D.;Stein, E. M.;Kantarjian, H. M.
通讯作者：
Kantarjian, H. M.